Results 241 to 250 of about 347,060 (291)

Design and evaluation of a multi-epitope DNA vaccine against HPV16. [PDF]

Hum Vaccin Immunother
Zhu L, Cui X, Yan Z, Tao Y, Shi L, Zhang X, Yao Y, Shi L.   +7 more
europepmc   +1 more source

Cost‐effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV‐positive women in cervical cancer screening

International Journal of Cancer, EarlyView.
What's New? Persistent infection with high‐risk human papillomavirus (HPV) causes most invasive cervical cancer cases, leading many countries to transition from cytology to primary HPV‐based screening. Despite the benefits, HPV‐based screening may also lead to unnecessary procedures, psychological burden, and strain on healthcare systems.
Kelsi R. Kroon, Johannes A. Bogaards, Johannes Berkhof   +2 more
wiley   +1 more source

Erratum: Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters. [PDF]

Mol Ther Methods Clin Dev
Tamming L, Duque D, Tran A, Lansdell C, Frahm G, Wu J, Fekete EEF, Creskey M, Thulasi Raman SN, Laryea E, Zhang W, Pfeifle A, Gravel C, Stalker A, Hashem AM, Chen W, Stuible M, Durocher Y, Safronetz D, Cao J, Wang L, Sauve S, Rosu-Myles M, Zhang X, Johnston MJW, Li X.   +25 more
europepmc   +1 more source

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions (VIVA trial): A randomized, double‐blind, placebo‐controlled trial

International Journal of Cancer, EarlyView.
What's New? Anal and vulvar high‐grade squamous intraepithelial lesions (HSILs) frequently recur following treatment. Additional genital and anal procedures, however, can be distressing for patients and are potentially disfiguring. This trial assessed whether the 9‐valent human papillomavirus (9vHPV) vaccine reduces HSIL recurrence risk or HPV ...
Helen C. Stankiewicz Karita, Amalia S. Magaret, David R. Doody, Jeffrey T. Schouten, Constance Mao, Warner K. Huh, Verena S. Grieco, Matthew A. Seymour, Dana Varon, Kelly H. Shrader, Long Fu Xi, Denise A. Galloway, Anna Wald, Margaret M. Madeleine   +13 more
wiley   +1 more source

A new multi-epitope DNA vaccine against Helicobacter Pylori infection in a BALB/c mouse model. [PDF]

Heliyon
Azami Z, Farahmand M, Kavousi M.
europepmc   +1 more source

Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites. [PDF]

J Allergy Clin Immunol Glob
Kayser T, Smulders R, Kusawake T, Wambre E, Chichili GR, Blauwet MB, Spence A, Patton M, Tabash R, DeBerg HA, Khosa S, Badorrek P, Hohlfeld JM, Ferslew BC.   +13 more
europepmc   +1 more source

Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine. [PDF]

NPJ Vaccines
Huang J, Luo G, Wang W, Lu Y, Wang M, Liu M, Zhu D, Chen S, Zhao X, Yang Q, Wu Y, Zhang S, Ou X, Tian B, Sun D, He Y, Wu Z, Cheng A, Jia R.   +18 more
europepmc   +1 more source

Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial. [PDF]

Hum Vaccin Immunother
Jia S, Shao C, Cheng X, Pan H, Wang Z, Xia Y, Xu J, Huai X, Leng D, Wang J, Zhao G, Wang B, Li J, Zhu F.   +13 more
europepmc   +1 more source

Correction: Therapeutic DNA vaccine attenuates itching and allergic inflammation in mice with established biting midge allergy. [PDF]

PLoS One
Lee MF, Chen YH, Song PP, Lin TM.
europepmc   +1 more source

Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. [PDF]

Vaccines (Basel)
Yang H, Zhou Y, Cheng X, Qiu C, Wang S, Xia Y, Huai X, Xiu Z, Wang J, He Y, Cao G, Wei Q, Wang J, Ai J, Zhang H, Zhang Y, Zhang J, Zhang W, Wang B.   +18 more
europepmc   +1 more source